Daily Medication Pearl: Zegalogue (Dasiglucagon) for Severe Hypoglycemia

Dasiglucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver.

Medication Pearl of the Day: Zegalogue (dasiglucagon)

Indication: Dasiglucagon is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

Insight:

  • Dasiglucagon autoinjector and prefilled syringe are for subcutaneous injection only.
  • Dosing: The dose in adults and pediatric patients aged 6 years and older is 0.6 mg.
  • Dosage forms: Dasiglucagon comes in 0.6 mg/0.6 mL single-dose autoinjector and 0.6 mg/0.6 mL single-dose prefilled syringe.
  • Adverse events: Most common adverse events seen from dasiglucagon include nausea, vomiting, headache, diarrhea, and injection site pain.
  • Mechanism of action: Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect.
  • Interactions: Patients taking beta-blockers may have a transient increase in pulse and blood pressure. In patients taking indomethacin, dasiglucagon may lose its ability to raise blood glucose or may produce hypoglycemia. In patients taking Warfarin, dasiglucagon may increase the anticoagulant effect of warfarin.
  • Manufacturer: Zealand Pharma

Sources:

zegalogue-prescribing-information.pdf

zegalogue image - Google Search